Guardant Health To Present Liquid Biopsy Data From More Than 10,000 Patients At The AACR Annual Meeting

REDWOOD CITY, Calif., April 1, 2016 /PRNewswire/ -- Guardant Health®, the leader in comprehensive liquid biopsies, announced it will present data on more than 10,000 clinical Guardant360® samples at the American Association for Cancer Research (AACR) 2016 annual meeting.

This first-of-its-kind analysis shows high concordance between genomic alterations detected by Guardant360 and those found in tissue-based population genomics studies derived from public datasets such as The Cancer Genome Atlas and the International Cancer Genome Consortium.

Additionally, Guardant360 detected resistance alterations not seen in treatment-naïve tissue cohorts, including MET amplifications and EGFR T790M. This finding suggests that sequencing archival tissue may miss important evolving alterations and hinder the selection of effective therapies for some late-stage cancer patients. The analysis also found that treatment decisions based on the detection of alterations at very low levels, even below 0.1% mutant-allele frequency, can lead to dramatic clinical response in patients.

The presentation is one of five abstracts highlighting the performance and clinical utility of Guardant Health's digital sequencing technology that have been accepted for oral and poster presentations at this year's AACR. The abstracts were submitted by researchers from Tel Aviv University, Thomas Jefferson University, Northwestern University, University of California, San Francisco, the Sungkyunkwan University School of Medicine, and Guardant Health.

Guardant360, the first comprehensive liquid biopsy, has been used by more than 2,000 oncologists to help match patients with advanced cancer to targeted therapies. Guardant Health's digital sequencing platform allows for comprehensive analysis of all major classes of somatic tumor alterations from a simple blood draw, with near-perfect specificity and high sensitivity.

The schedule of presentations:

Podium presentation:

Date and Time:  Tuesday, April 19 4:20-4:35 pm
Title:  Comparison of over 10,000 clinical NGS circulating tumor DNA profiles to tissue-derived genomic compendia
Abstract: 4343
Location: Room 243, Morial Convention Center
Poster Board Number: 22
Presenter:  Oliver Zill, Guardant Health

Poster presentations:

Date and Time:  Sunday, April 17 from 1-5 pm
Title:  Salvage MET amplification detection and therapy through cell-free DNA NGS in a progressing lung cancer patient
Abstract: 491
Location:  Section 23
Poster Board Number: 8
Presenter:  Nir Peled, Tel Aviv University
Collaborators: Oncotest Teva, Teva Pharmaceuticals

Date and Time:  Sunday, April 17 from 1-5 p.m. 
Title:  Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing
Abstract:  172
Location:  Section 6
Poster Board Number: 26
Presenter:  Laura Austin, Thomas Jefferson University
Collaborators: Northwestern University

Date and Time:  Sunday, April 17 from 1-5 p.m.
Title:  Post-surgical resection monitoring in early stage colorectal carcinoma patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity
Abstract:  506
Location:  Section 23
Poster Board Number:  23
Presenter:  Stefanie A. Mortimer
Collaborators: University of California San Francisco, Sungkyunkwan University School of Medicine

Date and Time:  Monday, April 18 from 1-5 p.m.
Title:  A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS
Abstract:  2240
Location:  Section 22
Poster Board Number:  2
Presenters:  Laura Austin, Thomas Jefferson University
Collaborators: Northwestern University

Guardant Health is also an exhibitor at the 2016 AACR Annual Meeting.  Company representatives will be available to provide additional information on Guardant Health and its product, Guardant360, at the company's booth, #312.  To learn more, visit www.guardanthealth.com.

About Guardant Health

Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.

Media Contact:
Mark de la Viña
Consort Partners for Guardant Health
Email:  [email protected] 
Phone:  415-282-4795

SOURCE Guardant Health

Related Links

http://www.guardanthealth.com